SeqOnce is accelerating life science discoveries and improving the human condition. From NGS to new detection technologies, we unlock hidden potential in existing platforms
Founded in 2014, SeqOnce was spun out of USC and is privately held. The founders have complementary skill sets with CSO Joseph Dunham’s strong background in molecular biology and technology development, James Gilmore in molecular biology and commercialization, and CEO Chris Angermayer’s expertise in finance and operations. SeqOnce is growing rapidly as it continues to launch new products in genomics, food safety, and pathogen detection.
Want to accelerate your sequencer or your CLIA lab? How about your career?
Actively seeking new investment. Contact us for more information.